Larazotide Acetate for Recovery
Tight-junction regulator developed for celiac disease; reduces intestinal permeability.
Why Larazotide Acetate for recovery?
Larazotide acetate (AT-1001) is an octapeptide zonulin antagonist that prevents tight-junction disassembly in the small intestine. Innovate Biopharmaceuticals advanced it to Phase 3 (CeDLara) as an adjunct for celiac disease but the trial failed its primary endpoint in 2022, and the program was paused. Still studied in long COVID and IBS.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. Larazotide Acetate fits this goal because its category (Recovery) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Reduces leaky-gut markers
Reference dosing by bodyweight
Anchored to the most-cited research dose (500 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 312–422 mcg |
| 60–75 kg / 132–165 lb | 383–518 mcg |
| 75–90 kg / 165–198 lb | 468–633 mcg |
| 90–105 kg / 198–231 lb | 553–747 mcg |
| >105 kg / >231 lb | 638–862 mcg |
Side effects to weigh against recovery benefit
- Headache
- Nausea
- Upper respiratory symptoms
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.